NO304551B1 - FremgangsmÕte ved fremstilling av sildenafil - Google Patents

FremgangsmÕte ved fremstilling av sildenafil

Info

Publication number
NO304551B1
NO304551B1 NO972481A NO972481A NO304551B1 NO 304551 B1 NO304551 B1 NO 304551B1 NO 972481 A NO972481 A NO 972481A NO 972481 A NO972481 A NO 972481A NO 304551 B1 NO304551 B1 NO 304551B1
Authority
NO
Norway
Prior art keywords
sildenafil
preparation
Prior art date
Application number
NO972481A
Other languages
English (en)
Other versions
NO972481L (no
NO972481D0 (no
Inventor
Peter James Dunn
Albert Shaw Wood
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10795332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO304551(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of NO972481D0 publication Critical patent/NO972481D0/no
Publication of NO972481L publication Critical patent/NO972481L/no
Publication of NO304551B1 publication Critical patent/NO304551B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
NO972481A 1996-06-14 1997-05-30 FremgangsmÕte ved fremstilling av sildenafil NO304551B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9612514.1A GB9612514D0 (en) 1996-06-14 1996-06-14 Novel process

Publications (3)

Publication Number Publication Date
NO972481D0 NO972481D0 (no) 1997-05-30
NO972481L NO972481L (no) 1997-12-15
NO304551B1 true NO304551B1 (no) 1999-01-11

Family

ID=10795332

Family Applications (2)

Application Number Title Priority Date Filing Date
NO972481A NO304551B1 (no) 1996-06-14 1997-05-30 FremgangsmÕte ved fremstilling av sildenafil
NO985064A NO306115B1 (no) 1996-06-14 1998-10-30 Fremgangsmåte ved fremstilling av sildenafil

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO985064A NO306115B1 (no) 1996-06-14 1998-10-30 Fremgangsmåte ved fremstilling av sildenafil

Country Status (48)

Country Link
US (2) US5955611A (no)
EP (2) EP0812845B1 (no)
JP (2) JP2866841B2 (no)
KR (1) KR100207352B1 (no)
CN (2) CN1106399C (no)
AP (1) AP717A (no)
AR (1) AR003401A1 (no)
AT (2) ATE246194T1 (no)
AU (1) AU697684B2 (no)
BG (1) BG62554B1 (no)
BR (1) BR9703580A (no)
CA (1) CA2207694C (no)
CO (1) CO4780028A1 (no)
CZ (1) CZ290942B6 (no)
DE (2) DE69723846T2 (no)
DK (2) DK0812845T3 (no)
DZ (1) DZ2247A1 (no)
EA (1) EA000102B1 (no)
EG (1) EG24123A (no)
ES (2) ES2201397T3 (no)
GB (1) GB9612514D0 (no)
GR (1) GR3031087T3 (no)
HK (1) HK1033459A1 (no)
HN (1) HN1997000072A (no)
HR (1) HRP970326B1 (no)
HU (1) HU224497B1 (no)
ID (1) ID18745A (no)
IL (3) IL125411A (no)
IN (5) IN187350B (no)
IS (2) IS1922B (no)
MA (1) MA24205A1 (no)
MX (1) MX9704433A (no)
NO (2) NO304551B1 (no)
NZ (1) NZ328084A (no)
OA (1) OA10426A (no)
PE (2) PE1299A1 (no)
PL (1) PL189333B1 (no)
PT (1) PT916675E (no)
RS (2) RS49653B (no)
SA (1) SA97180124B1 (no)
SG (1) SG50024A1 (no)
SI (2) SI0812845T1 (no)
SK (5) SK283895B6 (no)
TN (1) TNSN97102A1 (no)
TR (1) TR199700470A2 (no)
UA (1) UA27085C2 (no)
UY (2) UY24585A1 (no)
ZA (1) ZA975259B (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060222647A1 (en) * 1993-05-27 2006-10-05 Beavo Joseph A Methods and compositions for modulating the activity of PDE5
CN1281588C (zh) 1997-04-25 2006-10-25 美国辉瑞有限公司 制备吡唑并嘧啶酮类化合物的新型中间体
EP0992240A4 (en) * 1997-05-29 2003-04-16 Mochida Pharm Co Ltd THERAPEUTIC AGENT FOR TREATING ANERECTION
US6399618B1 (en) 1997-07-09 2002-06-04 Cardiome Pharma Corp Compositions and methods for modulating sexual activity
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
CN100430396C (zh) 1997-11-12 2008-11-05 拜耳医药保健股份公司 用作磷酸二酯酶抑制剂的2-苯基取代的咪唑并三嗪酮
US6251904B1 (en) * 1998-04-20 2001-06-26 Pfizer Inc. Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction
CA2235642C (en) 1998-05-15 2007-11-13 Torcan Chemical Ltd. Processes for preparing sildenafil
ES2220109T3 (es) * 1998-09-04 2004-12-01 Ortho-Mcneil Pharmaceutical, Inc. 5-heterociclilpirazolo (4,3-d) pirimidin-7-onas para el tratamiento de la disfuncion erectil masculina.
GB9822238D0 (en) * 1998-10-12 1998-12-09 Pfizer Ltd Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof
GB9823103D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823102D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
WO2000078760A1 (fr) * 1999-06-21 2000-12-28 The Biochemical Pharmaceutical Factory Of Zhuhai Sez Procede de preparation de sildenafil, agent et procede d'obtention d'un comprime mixte a base de sildenafil et de chlorhydrate d'apomorphine
CN1094492C (zh) * 1999-06-21 2002-11-20 杭州神鹰医药化工有限公司 西地那非的制备方法
CN1077108C (zh) * 1999-07-13 2002-01-02 成都地奥制药集团有限公司 用于制备药物昔多芬的前体化合物
WO2001019827A1 (en) * 1999-09-13 2001-03-22 Cipla Ltd. A novel process for the synthesis of sildenafil citrate
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
EA200200240A1 (ru) 1999-10-11 2002-10-31 Пфайзер Инк. 5-(2-ЗАМЕЩЕННЫЕ-5-ГЕТЕРОЦИКЛИЛСУЛЬФОНИЛПИРИД-3-ИЛ)-ДИГИДРОПИРАЗОЛО[4,3-d]ПИРИМИДИН-7-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
YU84702A (sh) * 2000-06-22 2005-09-19 Pfizer Inc. Novi postupak za pripremanje pirazolopirimidinona
US6667398B2 (en) 2000-06-22 2003-12-23 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
US6730786B2 (en) * 2000-06-22 2004-05-04 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
GB0015462D0 (en) * 2000-06-22 2000-08-16 Pfizer Ltd Novel process for the preparation of pyrazolopyrimidinones
YU51701A (sh) * 2000-07-28 2003-12-31 Pfizer Inc. Postupak za dobijanje jedinjenja pirazola/4,3-d/ pirimidin-7-ona i njihovih derivata
EP1176142A1 (en) * 2000-07-28 2002-01-30 Pfizer Inc. Process for the preparation of pyrazoles
US6407259B1 (en) 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
CN1127506C (zh) * 2001-06-29 2003-11-12 刘宝顺 一种治疗阳痿的新化合物
CA2457944C (en) * 2001-08-28 2009-09-29 Schering Corporation Polycyclic guanine phosphodiesterase v inhibitors
EP1719772A1 (en) 2002-05-31 2006-11-08 Schering Corporation Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
CN100374441C (zh) 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
CN100360531C (zh) * 2003-12-18 2008-01-09 中国人民解放军军事医学科学院放射与辐射医学研究所 用于预防或治疗阳萎和性冷淡的新吡唑并嘧啶类化合物
EP1779852A3 (en) * 2004-01-05 2007-05-09 Teva Pharmaceutical Industries Ltd. Processes for the production of sildenafil base and citrate salt
WO2005067936A2 (en) * 2004-01-05 2005-07-28 Teva Pharmaceutical Industries Ltd. Methods for the production of sildenafil base and citrate salt
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
WO2008074194A1 (fr) * 2006-12-21 2008-06-26 Topharman Shanghai Co., Ltd. Procédé de préparation du sildénafil et de ses intermédiaires
ES2310144B1 (es) 2007-06-15 2010-01-12 Galenicum Health, S.L. Intermedios para la preparacion de un inhibidor de la fosfodiesterasa tipo 5.
BRPI0823356A2 (pt) 2008-12-12 2015-06-16 Rhein Siegfried Sa De Cv Composição de liberação pulsátil de sildenafil e processo para prepará-la
MX2010006227A (es) 2010-06-07 2011-12-14 World Trade Imp Exp Wtie Ag Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.
CN102993205B (zh) * 2012-12-27 2015-04-15 华润赛科药业有限责任公司 一种高收率制备高纯度西地那非游离碱的纯化方法
CN103044330B (zh) * 2013-01-14 2018-11-13 常州亚邦制药有限公司 西地那非中间体4-氨基-1-甲基-3-正丙基吡唑-5-甲酰胺的绿色合成新工艺
CN105085526B (zh) * 2014-05-15 2017-08-01 重庆圣华曦药业股份有限公司 一种改进的西地那非制备方法
CN105753870B (zh) * 2016-04-01 2018-05-22 重庆康刻尔制药有限公司 一种西地那非杂质f及其制备方法和应用
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN105837578A (zh) * 2016-04-05 2016-08-10 重庆康刻尔制药有限公司 一种西地那非杂质d的合成方法
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
CN113493459B (zh) * 2020-04-07 2022-12-13 广州白云山医药集团股份有限公司白云山制药总厂 Pde5抑制剂化合物及其制备方法和应用
CN112961160A (zh) * 2021-03-05 2021-06-15 遂成药业股份有限公司 一种西地那非的改良合成工艺
CN113754612B (zh) * 2021-10-26 2023-09-26 山东安舜制药有限公司 一种西地那非中间体的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871843A (en) * 1983-10-18 1989-10-03 Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
CN1281588C (zh) * 1997-04-25 2006-10-25 美国辉瑞有限公司 制备吡唑并嘧啶酮类化合物的新型中间体
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase

Also Published As

Publication number Publication date
GB9612514D0 (en) 1996-08-14
TNSN97102A1 (fr) 2005-03-15
IN187319B (no) 2002-03-23
PT916675E (pt) 2003-11-28
ES2201397T3 (es) 2004-03-16
SK283895B6 (sk) 2004-04-06
TR199700470A2 (xx) 1998-01-21
IL121000A0 (en) 1997-11-20
IS1923B (is) 2004-03-15
IN187320B (no) 2002-03-23
HN1997000072A (es) 1997-12-26
ZA975259B (en) 1997-12-15
CO4780028A1 (es) 1999-05-26
HRP970326A2 (en) 1998-06-30
IL121000A (en) 2000-02-29
SI0916675T1 (en) 2003-12-31
US5955611A (en) 1999-09-21
NZ328084A (en) 1998-08-26
IN187350B (no) 2002-03-30
SK283893B6 (sk) 2004-04-06
HU9701048D0 (en) 1997-08-28
IN187317B (no) 2002-03-23
EP0812845B1 (en) 1999-07-14
AP717A (en) 1999-01-04
BR9703580A (pt) 1998-11-10
CZ290942B6 (cs) 2002-11-13
US6066735A (en) 2000-05-23
HRP970326B1 (en) 2000-10-31
KR100207352B1 (en) 1999-07-15
PL189333B1 (pl) 2005-07-29
IL125411A0 (en) 1999-03-12
IL125411A (en) 2000-02-29
UY24612A1 (es) 2000-09-29
EA199700061A1 (ru) 1997-12-30
UY24585A1 (es) 1997-12-02
ATE182150T1 (de) 1999-07-15
ATE246194T1 (de) 2003-08-15
NO972481L (no) 1997-12-15
SI0812845T1 (en) 1999-12-31
EA000102B1 (ru) 1998-08-27
PE1299A1 (es) 1999-01-13
IS4503A (is) 1997-12-15
CA2207694C (en) 1999-11-23
HU224497B1 (hu) 2005-10-28
CA2207694A1 (en) 1997-12-14
IS6634A (is) 2002-11-25
SA97180124A (ar) 2005-12-03
AU2487897A (en) 1997-12-18
DZ2247A1 (fr) 2002-12-18
NO306115B1 (no) 1999-09-20
JP3058863B2 (ja) 2000-07-04
PL320555A1 (en) 1997-12-22
HUP9701048A2 (hu) 1998-12-28
BG101569A (en) 1998-01-30
AU697684B2 (en) 1998-10-15
SA97180124B1 (ar) 2006-02-08
MX9704433A (es) 1998-11-30
CZ181197A3 (cs) 1998-03-18
SG50024A1 (en) 1998-06-15
EP0812845A1 (en) 1997-12-17
CN1282740A (zh) 2001-02-07
DE69723846T2 (de) 2004-03-04
DE69723846D1 (de) 2003-09-04
EP0916675A3 (en) 1999-07-14
SK283894B6 (sk) 2004-04-06
YU25497A (sh) 1998-12-23
SK283897B6 (sk) 2004-04-06
HK1033459A1 (en) 2001-08-31
NO972481D0 (no) 1997-05-30
RS20060484A (en) 2007-04-10
CN1149206C (zh) 2004-05-12
RS49924B (sr) 2008-09-29
DE69700321D1 (de) 1999-08-19
UA27085C2 (uk) 2000-02-28
IN187318B (no) 2002-03-23
JP2866841B2 (ja) 1999-03-08
IS1922B (is) 2004-03-15
SK74397A3 (en) 1998-06-03
JPH1081688A (ja) 1998-03-31
EP0916675A2 (en) 1999-05-19
GR3031087T3 (en) 1999-12-31
NO985064L (no) 1997-12-15
SK283896B6 (sk) 2004-04-06
CN1168376A (zh) 1997-12-24
NO985064D0 (no) 1998-10-30
AP9701009A0 (en) 1997-07-31
ID18745A (id) 1998-05-07
DE69700321T2 (de) 1999-11-04
BG62554B1 (bg) 2000-02-29
EG24123A (en) 2008-07-06
ES2134051T3 (es) 1999-09-16
OA10426A (en) 2001-12-07
JPH11171879A (ja) 1999-06-29
EP0916675B1 (en) 2003-07-30
KR980002051A (ko) 1998-03-30
DK0916675T3 (da) 2003-10-27
MA24205A1 (fr) 1997-12-31
AR003401A1 (es) 1998-08-05
HUP9701048A3 (en) 2000-10-30
RS49653B (sr) 2007-09-21
CN1106399C (zh) 2003-04-23
DK0812845T3 (da) 1999-11-29
PE20011303A1 (es) 2001-12-25

Similar Documents

Publication Publication Date Title
NO304551B1 (no) FremgangsmÕte ved fremstilling av sildenafil
NO994771D0 (no) FremgangsmÕte ved fremstilling av oligosakkarider
NO992375L (no) FremgangsmÕte for fremstilling av benzylethere
NO976121D0 (no) Fremgangsmåte for fremstilling av karbonylforbindelser
NO306943B1 (no) Fremgangsmåte for fremstilling av enantiomerene av O- demetyltramadol
NO974316D0 (no) Fremgangsmåte ved fremstilling av avfasede katetre
NO972240D0 (no) Fremgangsmåte ved fremstilling av N-fosfonometylglycin
NO983068D0 (no) FremgangsmÕte for fremstilling av bis-syklopentadienyl-dien komplekser
NO964482L (no) Fremgangsmåte ved fremstilling av doxorubicin
NO996432L (no) Fremgangsmåte for fremstilling av 4-substituert-1H-indol-3- glykosamider
NO985119D0 (no) FremgangsmÕte for fremstilling av dypp-belagte artikler
NO985535L (no) FremgangsmÕte for fremstilling av 1,3-alkandioler
NO955082L (no) Fremgangsmåte for fremstilling av glutardialdehyd
NO982503D0 (no) FremgangsmÕte ved fremstilling av dioksoazabicykloheksaner
NO20001793L (no) FremgangsmÕte ved fremstilling av azacykloalkylalkanoylpseudotetrapeptider
NO994749D0 (no) FremgangsmÕte ved fremstillingen av tetraazamakrocykler
NO304883B1 (no) FremgangsmÕte ved fremstilling av hydrazin-nitroform
NO980316D0 (no) Fremgangsmåte for fremstilling av polymerisater av N-vinylkarprolaktam
NO20013219L (no) Fremgangsmåte for fremstilling av trinatrium-pentacyanoamino- ferrat (II)
NO20003077L (no) FremgangsmÕte for fremstilling av klorbenzooksazolen
NO953459L (no) Fremgangsmåte ved fremstilling av cykloheptimidazolderivater
NO930436D0 (no) Fremgangsmaate ved fremstilling av baderom
NO20002476L (no) FremgangsmÕte for fremstilling av formylimidazoler
NO994557D0 (no) Fremgangsmaate for fremstilling av arylaminotriazolopyridiner
NO961577L (no) Fremgangsmåte for fremstilling av tre-polymer-kompositter

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees